ClinicalTrials.gg
Active, not recruitingNCT04157348MANDARAUpdated Nov 9, 2026Results posted

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

A Phase 3 interventional study of Benralizumab and Mepolizumab in Eosinophilic Granulomatous Vasculitis, sponsored by AstraZeneca. Active, not recruiting at 50 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Nov 9, 2026Study documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Churg-Strauss Syndrome with a site in United States — 8 open to participants now, 12 under way, 4 of them phase 3. Churg-Strauss Syndrome · United States.

Enrollment
3rd of 13
140 · median 60
Started
2019
with 1 other
Phase 3
6 of 26
2 open now
Primary completion
2023-08
later than 0 of 11 live
Registered
21st of 26
by date
Lead sponsor
3 of 26
AstraZeneca

Among the 26 studies in Churg-Strauss Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2019, is one of 6 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 21st registered.

Churg-Strauss Syndrome

61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.

Browse Churg-Strauss Syndrome studies →

Open to participants now

8 of the 26 studies in Churg-Strauss Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Churg-Strauss Syndrome studies recruiting now, 11 (79%) set no upper age limit and 3 (21%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Churg-Strauss Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy.

All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period is intended to allow each patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC (earlier enrolled patients may therefore be in the OLE for longer than 1 year).

03

Conditions studied

  • Eosinophilic Granulomatous Vasculitis

Browse trials for

Keywords

  • Benralizumab
  • Inhaled corticosteroids
  • Eosinophilic Granulomatous Vasculitis
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects age 18 years or older.
  2. EGPA diagnosis based on history or presence asthma and eosinophilia (>1.0x10\^9/L and/or >10% of leucocytes) and at least 2 of; with eosinophilic vasculitis or perivascular/granulomatous inflammation; mono-or polyneuropathy, non-fixed pulmonary infiltrates, sino-nasal abnormality; cardiomyopathy; glomerulonephritis; alveolar haemorrhage; palpable purpura; anti neutrophil cytoplasmic anti-body (ANCA) positivity (Myeloperoxidase or proteinease 3).
  3. History of relapsing (at least 1 confirmed EGPA relapse within last 2 years and > 12 weeks prior to screening), or (failure to attain remission, defined as BVAS=0 and oral (OCS) dose \<=7.5 mg/day of prednisolone or equivalent, following standard induction regimen for at least 3 months and within 6 months prior to screening, or recurrence of symptoms upon OCS tapering at any dose of ≥7.5 mg/day prednisolone or equivalent.

    If induction with glucocorticoidsalone, patient must have failed to attain remission after 3 months and the glucocorticoid dose must be ≥15 mg/day prednisolone or equivalent for the 4 weeks prior to randomization.

  4. Must be on a stable dose of oral prednisolone or prednisone of ≥7.5 mg/day (but not >50mg/day) for at least 4 weeks prior to randomization.
  5. If receiving therapy (excluding cyclophosphamide) the dose must be stable for the 4 weeks prior to randomization and during the study (dose reductions for safety reasons will be permitted).
  6. (F)\<450 msec or QTc(F)\<480 msec for patients with bundle branch block.
  7. Females of must use an acceptable method of from randomization for at least 12 weeks after the last study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
  2. Organ or life-threatening EGPA \< 3 months prior to screening
  3. Currently pregnant or breastfeeding, or planning to become pregnant during study participation.
  4. Current or history of malignancy, unless received curative therapy >5 years ago, or >1 year ago for basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix
  5. An untreated or helminth parasitic infection \< 24 weeks prior to screening
  6. Unstable liver disease
  7. Severe or , uncontrolled cardiovascular disease
  8. Other concurrent disease that may put the patient at risk, or may influence the results of the study, or the patients' ability to complete entire duration of the study
  9. Chronic or ongoing infectious disease requiring systemic anti-infective treatment
  10. Known immunodeficiency disorder or positive test
  11. Prior receipt of mepolizumab, reslizumab, dupilumab or benralizumab. Receipt of intravenous/intramuscular/subcutaneous within 4 weeks prior to randomization, receipt of omalizumab within 130 days prior to screening, rituximab within 6 months prior to screening (or B-cells not recovered), interferon-α or alemtuzumab within 6 months prior to screening, receipt of anti-tumor necrosis factor therapy within 12 weeks prior to screening or an non-biologic product within 30 days or 5 half-lives prior to screening, whichever is longer. Receipt of any other marketed or investigational biologic products within 4 months or 5 half-lives prior to screening, whichever is longer.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Benralizumab arm

    1x benralizumab SC injection + 3x placebo to mepolizumab SC injections

    Biological: Benralizumab · Biological: Placebo to Mepolizumab

  • Active comparator
    Mepolizumab arm

    3x mepolizumab SC injections + 1x placebo to benralizumab SC injection

    Biological: Mepolizumab · Biological: Placebo to Benralizumab

Interventions

  • BiologicalBenralizumab

    30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)

  • BiologicalMepolizumab

    3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)

  • BiologicalPlacebo to Mepolizumab

    Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)

  • BiologicalPlacebo to Benralizumab

    Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48

    Percentage of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 4 mg/day (main remission definition) at both Weeks 36 and 48.

    Time frame: Week 36 and Week 48

  2. Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48

    Supportive endpoint: Proportion of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 7.5 mg/day (supportive remission definition) at both Weeks 36 and 48.

    Time frame: Week 36 and Week 48

Secondary outcomes

  1. Total Accrued Duration of Remission During DB Treatment Period

    Total accrued duration of remission for the following categories: 0 week, \> 0 to \< 12 week, 12 to \< 24 week, 24 to \< 36 week, ≥ 36 week.

    Time frame: from baseline to end of DB period, 52 Weeks.

  2. Total Accrued Duration of Sustained Remission During DB Treatment Period

    Total accrued duration of sustained remission for the following categories: 0 week, \> 0 to \< 12 week, 12 to \< 24 week, 24 to \< 36 week, ≥ 36 week.

    Time frame: from baseline to end of DB period, 52 Weeks

  3. Time From Randomization to First Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse

    Time from randomization to first Eosinophilic Granulomatosis with Polyangiitis (EGPA) relapse, where relapse is defined as any of the following: * Active vasculitis (BVAS \> 0); OR * Active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR * Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions; warranting any of the following: * An increased dose of OCS therapy to \> 4 mg/day prednisolone total daily dose; OR * An increased dose or addition of immunosuppressive therapy; OR * Hospitalization related to EGPA worsening Calculated using the Kaplan-Meier technique.

    Time frame: from baseline to end of DB period, 52 Weeks

  4. Annualized Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse Rate

    Annualized Eosinophilic Granulomatosis with Polyangiitis (EGPA) relapse rate through end of DB treatment period. The estimate of annualized relapse rate (relapses per year) and the corresponding 95% CIs were calculated using a negative binomial model. The response variable in the model is the number of relapses experienced by a subject up to Week 52. The logarithm of the subject's corresponding follow-up time up to Week 52 was used as an offset variable to adjust for subjects having different follow-up times during which the events occur. The covariates in the model include treatment arm, baseline dose of prednisone, baseline BVAS and region.

    Time frame: from baseline to end of DB period, 52 Weeks

  5. Average Daily Dose of Prednisolone/Prednisone and Change From Baseline During Week 48 Through 52

    Average daily dose of prednisolone/prednisone and change from baseline during Week 48 through 52, or last 28 days prior to last double-blind assessment for those that withdrew

    Time frame: last 4 weeks of DB period

  6. Proportion of Patients With Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52

    Proportion of patients with average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: 0 mg; \>0 to ≤ 4 mg; \> 4 to ≤ 7.5 mg and \> 7.5 mg

    Time frame: last 4 weeks of DB period

  7. Percentage Reduction From Baseline in Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52

    Percentage reduction from baseline in average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: no reduction or withdrawal from treatment; \< 25% reduction; 25 to \< 50% reduction; 50 to \<75% reduction; 75 to \< 100% reduction; 100% reduction.

    Time frame: last 4 weeks of DB period

  8. Proportion of Subjects With Reduction From Baseline in Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52

    Proportion of subjects with reduction from baseline in average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: \>= 50% reduction; 100% reduction; OCS dose \<= 4 mg/day.

    Time frame: last 4 weeks of DB period

  9. Proportion of Subjects Who Achieve Clinical Benefit

    Proportion of subjects who achieved any clinical benefit definition 1 (defined as any of the following: * Main remission at any time in DB period * \>= 50% reduction in OCS dose in Weeks 48 to 52 * EGPA relapse free in DB period) and subjects who achieved complete response definition 1 (defined as meeting all the definition 1 criteria above.)

    Time frame: from baseline to end of DB period, 52 Weeks

  10. Proportion of Patients Who Have Achieved Remission Within the First 24 Weeks and Remained in Remission for Remainder of the Double-blind Treatment Period

    Proportion of patients who have achieved remission within the first 24 weeks and remained in remission for remainder of the double-blind treatment period

    Time frame: from baseline to end of DB period, 52 Weeks

  11. Change From Baseline in Birmingham Vasculitis Activity Score (BVAS)

    Birmingham Vasculitis Activity Score (BVAS) change from baseline by timepoint up to week 52. The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The total score on all 9 organ systems gives an indication of the disease activity of each patient at the time of scoring. Total scores range from 0 to 63, with higher scores indicating more active vasculitis.

    Time frame: from baseline to end of DB period, 52 Weeks

  12. Spirometry Change From Baseline by Timepoint up to Week 52: Pre-BD FEV1 (L)

    Pre-bronchodilator (BD) Forced Expiratory Volume during first second (FEV1) change from baseline by timepoint up to week 52

    Time frame: from baseline to end of DB period, 52 Weeks

  13. Spirometry Change From Baseline by Timepoint up to Week 52: Pre-BD FVC (L)

    Pre-bronchodilator (BD) Forced vital capacity (FVC) change from baseline by timepoint up to week 52

    Time frame: from baseline to end of DB period, 52 Weeks

  14. Change From Baseline in Vasculitis Damage Index (VDI)

    Vasculitis Damage Index (VDI) change from baseline by timepoint up to week 52. The VDI is divided into 11 organ systems and records items of damage, due to vasculitis, treatment or unrelated, that have occurred since the onset of vasculitis. Completion of the form provides a numerical score, ranging from 0 to 64, with a higher score indicating more damage.

    Time frame: from baseline to end of DB period, 52 Weeks

  15. Change From Baseline in Asthma Control Questionnaire (6-item Version) (ACQ-6)

    Asthma Control Questionnaire (6-item version) (ACQ-6) change from baseline by timepoint up to week 52. The ACQ-6 score is calculated by taking the mean of 6 equally weighted domains, with a range of 0 (well controlled) to 6 (extremely poorly controlled).

    Time frame: from baseline to end of DB period, 52 Weeks

  16. Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) Component: Physical Component Summary (PCS)

    Short Form 36-item health survey (version 2, acute recall) (SF-36v2) component Physical Component Summary (PCS) change from baseline by timepoint up to week 52. PCS score ranges from 10.8 to 75.5, where a higher score indicates better health.

    Time frame: from baseline to end of DB period, 52 Weeks

  17. Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) Component: Mental Component Summary (MCS)

    Short Form 36-item health survey (version 2, acute recall) (SF-36v2) component Mental Component Summary (MCS) change from baseline by timepoint up to week 52. MCS score ranges from 5.6 to 69.7, where a higher score indicates better health.

    Time frame: from baseline to end of DB period, 52 Weeks

  18. Change From Baseline in Sino-nasal Outcome Test-22 (SNOT-22) Total Score

    Sino-nasal Outcome Test-22 (SNOT-22) total score change from baseline by timepoint up to week 52. Patient reported symptom severity and symptom impact over the previous 2 weeks on 22 items are captured via a 6-point scale (0 = no problem to 5 = problem as bad as it can be). The total score is the sum of item scores and ranges from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: from baseline to end of DB period, 52 Weeks

  19. Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Runny Nose

    Sino-nasal Symptoms Questionnaire (SSQ) scores : symptom runny nose by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

    Time frame: from baseline to end of DB period, 52 Weeks

  20. Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Post-nasal Discharge

    Sino-nasal Symptoms Questionnaire (SSQ) scores : symptom Post-nasal discharge by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

    Time frame: from baseline to end of DB period, 52 Weeks

  21. Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Facial Pain/Pressure

    Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Facial pain/pressure by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

    Time frame: from baseline to end of DB period, 52 Weeks

  22. Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Loss or Reduction in Sense of Taste/Smell

    Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Loss or reduction in sense of taste/smell by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

    Time frame: from baseline to end of DB period, 52 Weeks

  23. Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Blockage/Congestion of Nose

    Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Blockage/congestion of nose by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

    Time frame: from baseline to end of DB period, 52 Weeks

  24. Patient Global Impression of Severity (PGIS) Category

    Patient Global Impression of Severity (PGIS) category by timepoint

    Time frame: from baseline to end of DB period, 52 Weeks

  25. Patient Global Impression of Change (PGIC) Category

    Patient Global Impression of Change (PGIC) category by timepoint

    Time frame: from baseline to week 4

  26. WPAI-GH Endpoint, Change From Baseline by Timepoint: Absenteeism (%)

    The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Subscale: Absenteeism (work time missed) (%) score, range 0-100.

    Time frame: from baseline to end of DB period, 52 Weeks

  27. WPAI-GH Endpoint, Change From Baseline by Timepoint up to Week 52: Subscale: Presenteeism (Impairment at Work) (%), Range 0-100.

    The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Presenteeism (%) score.

    Time frame: from baseline to end of DB period, 52 Weeks

  28. WPAI-GH Endpoint, Change From Baseline by Timepoint: Work Productivity Loss (%)

    The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Work productivity loss (%) score, range 0-100.

    Time frame: from baseline to end of DB period, 52 Weeks

  29. WPAI-GH Endpoint, Change From Baseline by Timepoint: Activity Impairment (%)

    The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Activity impairment (%) score, range 0-100.

    Time frame: from baseline to end of DB period, 52 Weeks

  30. Absolute Eosinophil Count, Change From Baseline

    Absolute eosinophil count, change from baseline by timepoint up to week 52

    Time frame: from baseline to end of DB period, 52 Weeks

07

Results

Posted Jan 14, 2025

Participant flow

140 participants were randomized to receive treatment in study D3253C00001 (MANDARA) with benralizumab 30 mg or mepolizumab 300 mg. Of the 140 patients randomized, 140 (100%) received treatment with study drug. 70 (50%) patients received benralizumab 30 mg and 70 (50%) patients received mepolizumab 300 mg.

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneBenralizumab 30 mgMepolizumab 300 mg
Started7070
Completed6967
Not completed13
Withdrew: Other reasons or due to covid-1911
Withdrew: Withdrawal by subject01
Withdrew: Adverse event01
Open-label Extension Period
Participant flow — Open-label Extension Period
MilestoneBenralizumab 30 mgMepolizumab 300 mg
Started6662
Completed00
Not completed6662
Withdrew: Adverse event11
Withdrew: Death01
Withdrew: Lack of efficacy22
Withdrew: Withdrawal by subject20
Withdrew: Ongoing6057
Withdrew: Other reasons11

Outcome measures

PrimaryNumber of Subjects Who Achieved Main Remission at Both Weeks 36 and 48

Percentage of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 4 mg/day (main remission definition) at both Weeks 36 and 48.

Time frame:
Week 36 and Week 48
Reported as:
Count of participants · Participants
Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 484040
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · p = 0.8773 · Difference in remission rates: 0.0121 · 95% CI -0.1411 to 0.1653The difference of remission rates (Benralizumab - Mepolizumab) are estimated using marginal standardization method in a logistic regression model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
PrimarySupportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48

Supportive endpoint: Proportion of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 7.5 mg/day (supportive remission definition) at both Weeks 36 and 48.

Time frame:
Week 36 and Week 48
Reported as:
Count of participants · Participants
Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 485552
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · Difference in remission rates: 0.0544 · 95% CI -0.0746 to 0.1834marginal standardization method
SecondaryTotal Accrued Duration of Remission During DB Treatment Period

Total accrued duration of remission for the following categories: 0 week, \> 0 to \< 12 week, 12 to \< 24 week, 24 to \< 36 week, ≥ 36 week.

Time frame:
from baseline to end of DB period, 52 Weeks.
Reported as:
Count of participants · Participants
Total Accrued Duration of Remission During DB Treatment Period
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
main remission — 0 week915
main remission — >0 to <12 weeks1310
main remission — 12 to <24 weeks88
main remission — 24 to <36 weeks2019
main remission — >=36 weeks2018
supportive remission — 0 week24
supportive remission — >0 to <12 weeks23
supportive remission — 12 to <24 weeks54
supportive remission — 24 to <36 weeks1615
supportive remission — >=36 weeks4544
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Proportional Odds Model · Odds ratio (or): 1.32 · 95% CI 0.72 to 2.40The odds ratio (Benralizumab vs. Mepolizumab) and its 95% CI are estimated with a proportional odds model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region. A \>1 odds ratio means Benralizumab is favored.
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Proportional Odds Model · Odds ratio (or): 1.12 · 95% CI 0.55 to 2.29The odds ratio (Benralizumab vs. Mepolizumab) and its 95% CI are estimated with a proportional odds model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region. A \>1 odds ratio means Benralizumab is favored.
SecondaryTotal Accrued Duration of Sustained Remission During DB Treatment Period

Total accrued duration of sustained remission for the following categories: 0 week, \> 0 to \< 12 week, 12 to \< 24 week, 24 to \< 36 week, ≥ 36 week.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Count of participants · Participants
Total Accrued Duration of Sustained Remission During DB Treatment Period
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
sustained main remission — 0 week915
sustained main remission — >0 to <12 weeks1513
sustained main remission — 12 to <24 weeks118
sustained main remission — 24 to <36 weeks1618
sustained main remission — >=36 weeks1916
sustained supportive remission — 0 week24
sustained supportive remission — >0 to <12 weeks56
sustained supportive remission — 12 to <24 weeks810
sustained supportive remission — 24 to <36 weeks1814
sustained supportive remission — >=36 weeks3736
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Proportional Odds Model · Odds ratio (or): 1.34 · 95% CI 0.74 to 2.44The odds ratio (Benralizumab vs. Mepolizumab) and its 95% CI are estimated with a proportional odds model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Proportional Odds Model · Odds ratio (or): 1.23 · 95% CI 0.64 to 2.34The odds ratio (Benralizumab vs. Mepolizumab) and its 95% CI are estimated with a proportional odds model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region. A \>1 odds ratio means Benralizumab is favored.
SecondaryTime From Randomization to First Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse

Time from randomization to first Eosinophilic Granulomatosis with Polyangiitis (EGPA) relapse, where relapse is defined as any of the following: * Active vasculitis (BVAS \> 0); OR * Active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR * Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions; warranting any of the following: * An increased dose of OCS therapy to \> 4 mg/day prednisolone total daily dose; OR * An increased dose or addition of immunosuppressive therapy; OR * Hospitalization related to EGPA worsening Calculated using the Kaplan-Meier technique.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Number · percentage of subjects
Time From Randomization to First Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse
percentage of subjectsBenralizumab 30 mgMepolizumab 300 mg
relapse-percent subject with at least 1 relapse by week 165.71 (2.18 to 14.51)4.29 (1.40 to 12.70)
relapse-percent subject with at least 1 relapse by week 3217.14 (10.12 to 28.21)20.24 (12.52 to 31.77)
relapse-percent subject with at least 1 relapse by week 5230.00 (20.71 to 42.21)29.10 (19.85 to 41.40)
major relapse-percent subject with at least 1 relapse by week 160 (0 to 0)0 (0 to 0)
major relapse-percent subject with at least 1 relapse by week 320 (0 to 0)0 (0 to 0)
major relapse-percent subject with at least 1 relapse by week 520 (0 to 0)2.94 (0.74 to 11.25)
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Cox · Hazard ratio (hr): 0.98 · 95% CI 0.53 to 1.82The HR (Benralizumab vs. Mepolizumab) and 95% CI are estimated using a Cox regression model with Efron method to control for ties. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
SecondaryAnnualized Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse Rate

Annualized Eosinophilic Granulomatosis with Polyangiitis (EGPA) relapse rate through end of DB treatment period. The estimate of annualized relapse rate (relapses per year) and the corresponding 95% CIs were calculated using a negative binomial model. The response variable in the model is the number of relapses experienced by a subject up to Week 52. The logarithm of the subject's corresponding follow-up time up to Week 52 was used as an offset variable to adjust for subjects having different follow-up times during which the events occur. The covariates in the model include treatment arm, baseline dose of prednisone, baseline BVAS and region.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · relapses per year
Annualized Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse Rate
relapses per yearBenralizumab 30 mgMepolizumab 300 mg
Annualized Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse Rate0.50 (0.30 to 0.83)0.49 (0.28 to 0.86)
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · negative binomial model · Risk ratio (rr): 1.03 · 95% CI 0.56 to 1.90The rate ratio (Benralizumab/Mepolizumab) and the corresponding 95% CI are calculated using a negative binomial model. The covariates in the model include treatment arm, baseline dose of prednisone, baseline BVAS and region.
SecondaryAverage Daily Dose of Prednisolone/Prednisone and Change From Baseline During Week 48 Through 52

Average daily dose of prednisolone/prednisone and change from baseline during Week 48 through 52, or last 28 days prior to last double-blind assessment for those that withdrew

Time frame:
last 4 weeks of DB period
Reported as:
Mean · mg
Average Daily Dose of Prednisolone/Prednisone and Change From Baseline During Week 48 Through 52
mgBenralizumab 30 mgMepolizumab 300 mg
average daily dose3.01 ± 3.7763.43 ± 4.124
change from baseline of average daily dose-8.08 ± 4.575-7.52 ± 7.070
SecondaryProportion of Patients With Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52

Proportion of patients with average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: 0 mg; \>0 to ≤ 4 mg; \> 4 to ≤ 7.5 mg and \> 7.5 mg

Time frame:
last 4 weeks of DB period
Reported as:
Count of participants · Participants
Proportion of Patients With Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
02919
>0 to <=4.0 mg1930
>4.0 to <=7.5 mg1513
>7.5 mg78
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · proportional odds model · Odds ratio (or): 1.38 · 95% CI 0.75 to 2.54The odds ratio (Benralizumab 30 mg vs. Mepolizumab 300 mg) and 95% CI are estimated using a proportional odds model. The covariates in the model include treatment arm, baseline dose of prednisone, baseline BVAS and region.
SecondaryPercentage Reduction From Baseline in Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52

Percentage reduction from baseline in average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: no reduction or withdrawal from treatment; \< 25% reduction; 25 to \< 50% reduction; 50 to \<75% reduction; 75 to \< 100% reduction; 100% reduction.

Time frame:
last 4 weeks of DB period
Reported as:
Count of participants · Participants
Percentage Reduction From Baseline in Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
no reduction or withdrawal from IP before week 4837
<25% reduction02
25 to <50% reduction89
50 to <75% reduction1917
75 to <100% reduction1117
100% reduction2918
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · proportional odds model · Odds ratio (or): 1.76 · 95% CI 0.96 to 3.22The odds ratio (Benralizumab 30 mg vs. Mepolizumab 300 mg) for higher % reduction and 95% CI are estimated using a proportional odds model. The covariates in the model include treatment arm, baseline dose of prednisone, baseline BVAS and region.
SecondaryProportion of Subjects With Reduction From Baseline in Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52

Proportion of subjects with reduction from baseline in average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: \>= 50% reduction; 100% reduction; OCS dose \<= 4 mg/day.

Time frame:
last 4 weeks of DB period
Reported as:
Count of participants · Participants
Proportion of Subjects With Reduction From Baseline in Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
>=50% reduction5952
100% reduction2918
OCS dose <=4 mg/day4849
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · Difference in proportions: 0.1079 · 95% CI -0.0225 to 0.2383The difference of proportions (Benralizumab - Mepolizumab) and 95% CI are estimated using marginal standardization method in a logistic regression model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · Difference in proportions: 0.1569 · 95% CI 0.0067 to 0.3017The difference of proportions (Benralizumab - Mepolizumab) and 95% CI are estimated using marginal standardization method in a logistic regression model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · Difference in proportions: -0.0068 · 95% CI -0.1555 to 0.1418The difference of proportions (Benralizumab - Mepolizumab) and 95% CI are estimated using marginal standardization method in a logistic regression model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
SecondaryProportion of Subjects Who Achieve Clinical Benefit

Proportion of subjects who achieved any clinical benefit definition 1 (defined as any of the following: * Main remission at any time in DB period * \>= 50% reduction in OCS dose in Weeks 48 to 52 * EGPA relapse free in DB period) and subjects who achieved complete response definition 1 (defined as meeting all the definition 1 criteria above.)

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieve Clinical Benefit
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
any clinical benefit-definition 16663
Complete response - definition 14339
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · Difference in response rates: 0.046 · 95% CI -0.0422 to 0.1341The difference of response rates (Benralizumab - Mepolizumab) and 95% CI are estimated using marginal standardization method in a logistic regression model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · Difference in response rates: 0.0790 · 95% CI -0.0732 to 0.2312The difference of response rates (Benralizumab - Mepolizumab) and 95% CI are estimated using marginal standardization method in a logistic regression model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
SecondaryProportion of Patients Who Have Achieved Remission Within the First 24 Weeks and Remained in Remission for Remainder of the Double-blind Treatment Period

Proportion of patients who have achieved remission within the first 24 weeks and remained in remission for remainder of the double-blind treatment period

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Count of participants · Participants
Proportion of Patients Who Have Achieved Remission Within the First 24 Weeks and Remained in Remission for Remainder of the Double-blind Treatment Period
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
main remission2827
supportive remission4140
Statistical analysis
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · Difference in remission rates: 0.0554 · 95% CI -0.0930 to 0.2037The difference of remission rates (Benralizumab - Mepolizumab) and 95% CI are estimated using marginal standardization method in a logistic regression model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
  • Benralizumab 30 mg vs Mepolizumab 300 mg · Regression, Logistic · Difference in remission rates: 0.0467 · 95% CI -0.1021 to 0.1956The difference of remission rates (Benralizumab - Mepolizumab) and 95% CI are estimated using marginal standardization method in a logistic regression model. The covariates include treatment arm, baseline dose of prednisone, baseline BVAS and region.
SecondaryChange From Baseline in Birmingham Vasculitis Activity Score (BVAS)

Birmingham Vasculitis Activity Score (BVAS) change from baseline by timepoint up to week 52. The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The total score on all 9 organ systems gives an indication of the disease activity of each patient at the time of scoring. Total scores range from 0 to 63, with higher scores indicating more active vasculitis.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Birmingham Vasculitis Activity Score (BVAS)
scores on a scaleBenralizumab 30 mgMepolizumab 300 mg
week 4-1.19 (-1.62 to -0.76)-1.14 (-1.57 to -0.70)
week 8-1.33 (-1.75 to -0.90)-1.74 (-2.16 to -1.31)
week 12-1.79 (-2.03 to -1.55)-1.66 (-1.90 to -1.42)
week 16-1.85 (-2.04 to -1.65)-1.80 (-2.00 to -1.59)
week 20-1.73 (-2.01 to -1.44)-1.82 (-2.10 to -1.53)
week 24-1.59 (-1.88 to -1.31)-1.74 (-2.02 to -1.45)
week 28-1.94 (-2.09 to -1.79)-1.95 (-2.10 to -1.80)
week 32-1.92 (-2.04 to -1.80)-1.93 (-2.05 to -1.81)
week 36-1.98 (-2.29 to -1.66)-1.65 (-1.98 to -1.33)
week 40-1.84 (-2.01 to -1.67)-1.89 (-2.07 to -1.72)
week 44-1.84 (-2.00 to -1.68)-1.96 (-2.13 to -1.80)
week 48-1.80 (-2.04 to -1.56)-1.92 (-2.17 to -1.66)
week 52-1.85 (-2.37 to -1.34)-1.32 (-1.84 to -0.80)
SecondarySpirometry Change From Baseline by Timepoint up to Week 52: Pre-BD FEV1 (L)

Pre-bronchodilator (BD) Forced Expiratory Volume during first second (FEV1) change from baseline by timepoint up to week 52

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · L
Spirometry Change From Baseline by Timepoint up to Week 52: Pre-BD FEV1 (L)
LBenralizumab 30 mgMepolizumab 300 mg
week 120.13 (0.0 to 0.2)0.11 (0.0 to 0.2)
week 240.11 (0.0 to 0.2)0.13 (0.0 to 0.2)
week 360.10 (-0.0 to 0.2)0.11 (0.0 to 0.2)
week 480.03 (-0.1 to 0.1)0.06 (-0.0 to 0.2)
week 520.06 (-0.0 to 0.2)0.01 (-0.1 to 0.1)
SecondarySpirometry Change From Baseline by Timepoint up to Week 52: Pre-BD FVC (L)

Pre-bronchodilator (BD) Forced vital capacity (FVC) change from baseline by timepoint up to week 52

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · L
Spirometry Change From Baseline by Timepoint up to Week 52: Pre-BD FVC (L)
LBenralizumab 30 mgMepolizumab 300 mg
week 120.13 (0.0 to 0.2)0.05 (-0.0 to 0.2)
week 240.09 (0.0 to 0.2)0.04 (-0.1 to 0.1)
week 360.05 (-0.0 to 0.1)0.03 (-0.1 to 0.1)
week 480.03 (-0.1 to 0.1)0.00 (-0.1 to 0.1)
week 520.01 (-0.1 to 0.1)-0.04 (-0.2 to 0.1)
SecondaryChange From Baseline in Vasculitis Damage Index (VDI)

Vasculitis Damage Index (VDI) change from baseline by timepoint up to week 52. The VDI is divided into 11 organ systems and records items of damage, due to vasculitis, treatment or unrelated, that have occurred since the onset of vasculitis. Completion of the form provides a numerical score, ranging from 0 to 64, with a higher score indicating more damage.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · score
Change From Baseline in Vasculitis Damage Index (VDI)
scoreBenralizumab 30 mgMepolizumab 300 mg
week 240.06 (-0.00 to 0.12)0.04 (-0.02 to 0.10)
week 520.13 (0.04 to 0.22)0.10 (0.01 to 0.20)
SecondaryChange From Baseline in Asthma Control Questionnaire (6-item Version) (ACQ-6)

Asthma Control Questionnaire (6-item version) (ACQ-6) change from baseline by timepoint up to week 52. The ACQ-6 score is calculated by taking the mean of 6 equally weighted domains, with a range of 0 (well controlled) to 6 (extremely poorly controlled).

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · score
Change From Baseline in Asthma Control Questionnaire (6-item Version) (ACQ-6)
scoreBenralizumab 30 mgMepolizumab 300 mg
week 1-4-0.34 (-0.47 to -0.21)-0.31 (-0.44 to -0.18)
week 5-8-0.56 (-0.68 to -0.43)-0.49 (-0.61 to -0.36)
week 9-12-0.55 (-0.68 to -0.42)-0.52 (-0.65 to -0.39)
week 13-16-0.62 (-0.76 to -0.48)-0.48 (-0.62 to -0.33)
week 17-20-0.59 (-0.75 to -0.43)-0.47 (-0.63 to -0.31)
week 21-24-0.59 (-0.76 to -0.43)-0.53 (-0.70 to -0.37)
week 25-28-0.65 (-0.80 to -0.49)-0.49 (-0.64 to -0.33)
week 29-32-0.56 (-0.73 to -0.39)-0.50 (-0.67 to -0.33)
week 33-36-0.57 (-0.73 to -0.41)-0.55 (-0.71 to -0.39)
week 37-40-0.57 (-0.72 to -0.42)-0.54 (-0.69 to -0.39)
week 41-44-0.58 (-0.73 to -0.43)-0.60 (-0.75 to -0.45)
week 45-48-0.61 (-0.76 to -0.45)-0.64 (-0.79 to -0.48)
week 49-52-0.57 (-0.72 to -0.41)-0.61 (-0.77 to -0.46)
SecondaryChange From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) Component: Physical Component Summary (PCS)

Short Form 36-item health survey (version 2, acute recall) (SF-36v2) component Physical Component Summary (PCS) change from baseline by timepoint up to week 52. PCS score ranges from 10.8 to 75.5, where a higher score indicates better health.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · score
Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) Component: Physical Component Summary (PCS)
scoreBenralizumab 30 mgMepolizumab 300 mg
week 10.68 (-0.4 to 1.7)0.88 (-0.2 to 1.9)
week 41.18 (-0.1 to 2.5)1.11 (-0.2 to 2.4)
week 81.56 (0.3 to 2.8)1.46 (0.2 to 2.7)
week 121.30 (-0.0 to 2.6)1.31 (-0.0 to 2.6)
week 161.24 (-0.2 to 2.7)1.85 (0.4 to 3.3)
week 281.54 (-0.0 to 3.1)2.12 (0.6 to 3.7)
week 401.73 (0.4 to 3.1)2.28 (0.9 to 3.6)
week 520.29 (-1.3 to 1.9)2.45 (0.8 to 4.0)
SecondaryChange From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) Component: Mental Component Summary (MCS)

Short Form 36-item health survey (version 2, acute recall) (SF-36v2) component Mental Component Summary (MCS) change from baseline by timepoint up to week 52. MCS score ranges from 5.6 to 69.7, where a higher score indicates better health.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · score
Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) Component: Mental Component Summary (MCS)
scoreBenralizumab 30 mgMepolizumab 300 mg
week 10.90 (-0.7 to 2.5)-0.13 (-1.7 to 1.5)
week 40.06 (-1.8 to 1.9)0.58 (-1.2 to 2.4)
week 80.64 (-1.3 to 2.6)1.05 (-0.9 to 3.0)
week 120.04 (-1.9 to 2.0)1.44 (-0.5 to 3.4)
week 160.29 (-1.8 to 2.3)2.18 (0.1 to 4.2)
week 28-0.03 (-2.0 to 1.9)2.03 (0.1 to 4.0)
week 400.77 (-1.5 to 3.0)2.39 (0.2 to 4.6)
week 521.13 (-1.1 to 3.4)2.19 (-0.1 to 4.4)
SecondaryChange From Baseline in Sino-nasal Outcome Test-22 (SNOT-22) Total Score

Sino-nasal Outcome Test-22 (SNOT-22) total score change from baseline by timepoint up to week 52. Patient reported symptom severity and symptom impact over the previous 2 weeks on 22 items are captured via a 6-point scale (0 = no problem to 5 = problem as bad as it can be). The total score is the sum of item scores and ranges from 0 to 110 (higher scores indicate poorer outcomes).

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · score
Change From Baseline in Sino-nasal Outcome Test-22 (SNOT-22) Total Score
scoreBenralizumab 30 mgMepolizumab 300 mg
week 4-4.34 (-7.2 to -1.5)-4.32 (-7.2 to -1.5)
week 8-5.79 (-8.8 to -2.8)-6.42 (-9.4 to -3.4)
week 12-5.30 (-8.5 to -2.1)-6.35 (-9.5 to -3.2)
week 16-6.04 (-9.2 to -2.9)-6.04 (-9.2 to -2.9)
week 28-7.89 (-11.0 to -4.8)-7.59 (-10.7 to -4.5)
week 40-5.05 (-8.2 to -1.9)-8.33 (-11.6 to -5.1)
week 52-5.98 (-9.3 to -2.7)-6.35 (-9.7 to -3.0)
SecondarySino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Runny Nose

Sino-nasal Symptoms Questionnaire (SSQ) scores : symptom runny nose by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Runny Nose
scoreBenralizumab 30 mgMepolizumab 300 mg
baseline1.0 ± 0.851.2 ± 1.00
week 1-41.4 ± 0.951.2 ± 0.97
week 5-81.3 ± 0.921.0 ± 0.86
week 9-121.4 ± 1.001.0 ± 0.88
week 13-161.4 ± 0.991.2 ± 0.92
week 17-201.3 ± 0.981.1 ± 0.96
week 21-241.3 ± 0.881.2 ± 0.86
week 25-281.1 ± 0.951.2 ± 0.90
week 29-321.2 ± 0.901.1 ± 0.99
week 33-361.3 ± 0.871.0 ± 0.90
week 37-401.3 ± 0.961.0 ± 0.87
week 41-441.1 ± 0.860.9 ± 0.76
week 45-481.3 ± 0.980.9 ± 0.87
week 49-521.2 ± 0.981.0 ± 0.96
SecondarySino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Post-nasal Discharge

Sino-nasal Symptoms Questionnaire (SSQ) scores : symptom Post-nasal discharge by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Post-nasal Discharge
scoreBenralizumab 30 mgMepolizumab 300 mg
baseline1.1 ± 1.001.2 ± 1.06
week 1-41.4 ± 0.881.3 ± 1.00
week 5-81.2 ± 0.941.2 ± 0.85
week 9-121.2 ± 1.011.2 ± 0.98
week 13-161.2 ± 0.961.2 ± 0.94
week 17-201.2 ± 0.991.3 ± 0.99
week 21-241.2 ± 0.931.2 ± 0.98
week 25-281.1 ± 1.051.1 ± 0.88
week 29-321.1 ± 0.971.1 ± 0.99
week 33-361.1 ± 0.881.0 ± 0.95
week 37-401.2 ± 0.960.9 ± 0.81
week 41-441.1 ± 1.050.9 ± 0.83
week 45-481.1 ± 1.031.0 ± 0.89
week 49-521.1 ± 0.961.0 ± 0.95
SecondarySino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Facial Pain/Pressure

Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Facial pain/pressure by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Facial Pain/Pressure
scoreBenralizumab 30 mgMepolizumab 300 mg
baseline0.7 ± 0.950.6 ± 0.94
week 1-40.9 ± 0.970.8 ± 0.99
week 5-80.9 ± 1.080.8 ± 0.93
week 9-120.9 ± 1.010.8 ± 0.88
week 13-160.8 ± 0.930.6 ± 0.80
week 17-200.9 ± 0.970.7 ± 0.93
week 21-240.8 ± 0.880.6 ± 0.81
week 25-280.7 ± 0.950.6 ± 0.89
week 29-320.7 ± 0.890.6 ± 0.90
week 33-360.6 ± 0.860.6 ± 0.89
week 37-400.8 ± 1.010.6 ± 0.82
week 41-440.7 ± 0.920.6 ± 0.82
week 45-480.7 ± 0.900.7 ± 0.98
week 49-520.7 ± 0.900.6 ± 0.87
SecondarySino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Loss or Reduction in Sense of Taste/Smell

Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Loss or reduction in sense of taste/smell by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Loss or Reduction in Sense of Taste/Smell
scoreBenralizumab 30 mgMepolizumab 300 mg
baseline1.3 ± 1.321.2 ± 1.43
week 1-41.3 ± 1.361.2 ± 1.45
week 5-81.2 ± 1.281.1 ± 1.35
week 9-121.2 ± 1.291.0 ± 1.36
week 13-161.3 ± 1.321.1 ± 1.41
week 17-201.3 ± 1.361.1 ± 1.32
week 21-241.4 ± 1.441.2 ± 1.33
week 25-281.3 ± 1.391.1 ± 1.37
week 29-321.4 ± 1.341.0 ± 1.38
week 33-361.4 ± 1.391.1 ± 1.35
week 37-401.5 ± 1.381.1 ± 1.31
week 41-441.5 ± 1.431.0 ± 1.29
week 45-481.5 ± 1.441.1 ± 1.36
week 49-521.5 ± 1.401.1 ± 1.35
SecondarySino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Blockage/Congestion of Nose

Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Blockage/congestion of nose by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Blockage/Congestion of Nose
scoreBenralizumab 30 mgMepolizumab 300 mg
baseline1.3 ± 1.071.4 ± 1.15
week 1-41.5 ± 0.991.4 ± 0.96
week 5-81.5 ± 0.961.4 ± 1.03
week 9-121.5 ± 0.901.3 ± 1.00
week 13-161.6 ± 1.141.4 ± 1.09
week 17-201.7 ± 1.121.4 ± 1.04
week 21-241.6 ± 1.061.3 ± 1.05
week 25-281.4 ± 1.031.4 ± 1.03
week 29-321.5 ± 0.991.4 ± 1.13
week 33-361.5 ± 0.921.3 ± 1.09
week 37-401.6 ± 1.011.3 ± 1.14
week 41-441.5 ± 1.081.2 ± 0.96
week 45-481.5 ± 1.131.3 ± 1.11
week 49-521.5 ± 1.071.3 ± 1.03
SecondaryPatient Global Impression of Severity (PGIS) Category

Patient Global Impression of Severity (PGIS) category by timepoint

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Count of participants · Participants
Patient Global Impression of Severity (PGIS) Category
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
baseline — No symptoms82
baseline — Very mild819
baseline — Mild1816
baseline — Moderate2826
baseline — Severe75
baseline — Very severe12
baseline — Missing00
week 1 — No symptoms44
week 1 — Very mild1515
week 1 — Mild2116
week 1 — Moderate2426
week 1 — Severe46
week 1 — Very severe10
week 1 — Missing13
week 2 — No symptoms125
week 2 — Very mild1427
week 2 — Mild2111
week 2 — Moderate2018
week 2 — Severe13
week 2 — Very severe01
week 2 — Missing25
week 3 — No symptoms98
week 3 — Very mild2324
week 3 — Mild1619
week 3 — Moderate1813
week 3 — Severe23
week 3 — Very severe00
week 3 — Missing23
week 4 — No symptoms68
week 4 — Very mild1720
week 4 — Mild1513
week 4 — Moderate2623
week 4 — Severe35
week 4 — Very severe10
week 4 — Missing21
week 5 — No symptoms126
week 5 — Very mild2031
week 5 — Mild2415
week 5 — Moderate1214
week 5 — Severe03
week 5 — Very severe00
week 5 — Missing21
week 6 — No symptoms89
week 6 — Very mild2933
week 6 — Mild1813
week 6 — Moderate139
week 6 — Severe11
week 6 — Very severe02
week 6 — Missing13
week 7 — No symptoms812
week 7 — Very mild2523
week 7 — Mild1820
week 7 — Moderate1410
week 7 — Severe31
week 7 — Very severe01
week 7 — Missing23
week 8 — No symptoms45
week 8 — Very mild1824
week 8 — Mild1815
week 8 — Moderate2120
week 8 — Severe63
week 8 — Very severe12
week 8 — Missing21
week 9 — No symptoms714
week 9 — Very mild2622
week 9 — Mild1717
week 9 — Moderate1413
week 9 — Severe42
week 9 — Very severe00
week 9 — Missing22
week 10 — No symptoms711
week 10 — Very mild2124
week 10 — Mild2422
week 10 — Moderate137
week 10 — Severe12
week 10 — Very severe20
week 10 — Missing24
week 11 — No symptoms713
week 11 — Very mild2724
week 11 — Mild1715
week 11 — Moderate1415
week 11 — Severe21
week 11 — Very severe10
week 11 — Missing22
week 12 — No symptoms68
week 12 — Very mild1820
week 12 — Mild1916
week 12 — Moderate1720
week 12 — Severe64
week 12 — Very severe20
week 12 — Missing22
week 13 — No symptoms69
week 13 — Very mild2624
week 13 — Mild2218
week 13 — Moderate1115
week 13 — Severe23
week 13 — Very severe10
week 13 — Missing21
week 14 — No symptoms611
week 14 — Very mild2924
week 14 — Mild1515
week 14 — Moderate1515
week 14 — Severe21
week 14 — Very severe01
week 14 — Missing33
week 15 — No symptoms611
week 15 — Very mild3123
week 15 — Mild1217
week 15 — Moderate1616
week 15 — Severe31
week 15 — Very severe00
week 15 — Missing22
week 16 — No symptoms35
week 16 — Very mild2321
week 16 — Mild1726
week 16 — Moderate1913
week 16 — Severe51
week 16 — Very severe11
week 16 — Missing23
week 17 — No symptoms136
week 17 — Very mild2328
week 17 — Mild1419
week 17 — Moderate1911
week 17 — Severe12
week 17 — Very severe01
week 17 — Missing03
week 18 — No symptoms77
week 18 — Very mild2728
week 18 — Mild1413
week 18 — Moderate1818
week 18 — Severe02
week 18 — Very severe20
week 18 — Missing22
week 19 — No symptoms711
week 19 — Very mild2725
week 19 — Mild1417
week 19 — Moderate1415
week 19 — Severe50
week 19 — Very severe21
week 19 — Missing11
week 20 — No symptoms813
week 20 — Very mild2220
week 20 — Mild1821
week 20 — Moderate1411
week 20 — Severe71
week 20 — Very severe01
week 20 — Missing13
week 21 — No symptoms715
week 21 — Very mild2624
week 21 — Mild1312
week 21 — Moderate1713
week 21 — Severe52
week 21 — Very severe10
week 21 — Missing14
week 22 — No symptoms1312
week 22 — Very mild1924
week 22 — Mild1916
week 22 — Moderate1612
week 22 — Severe31
week 22 — Very severe00
week 22 — Missing05
week 23 — No symptoms813
week 23 — Very mild2424
week 23 — Mild2019
week 23 — Moderate1413
week 23 — Severe11
week 23 — Very severe20
week 23 — Missing10
week 24 — No symptoms713
week 24 — Very mild2522
week 24 — Mild2016
week 24 — Moderate1416
week 24 — Severe32
week 24 — Very severe00
week 24 — Missing11
week 25 — No symptoms1113
week 25 — Very mild2522
week 25 — Mild1917
week 25 — Moderate1014
week 25 — Severe40
week 25 — Very severe00
week 25 — Missing14
week 26 — No symptoms1213
week 26 — Very mild2522
week 26 — Mild1714
week 26 — Moderate1115
week 26 — Severe32
week 26 — Very severe11
week 26 — Missing13
week 27 — No symptoms1015
week 27 — Very mild2821
week 27 — Mild1617
week 27 — Moderate1510
week 27 — Severe02
week 27 — Very severe10
week 27 — Missing05
week 28 — No symptoms69
week 28 — Very mild2121
week 28 — Mild2318
week 28 — Moderate1416
week 28 — Severe42
week 28 — Very severe10
week 28 — Missing14
week 29 — No symptoms612
week 29 — Very mild2821
week 29 — Mild1719
week 29 — Moderate1510
week 29 — Severe23
week 29 — Very severe00
week 29 — Missing25
week 30 — No symptoms718
week 30 — Very mild2216
week 30 — Mild2518
week 30 — Moderate119
week 30 — Severe32
week 30 — Very severe01
week 30 — Missing26
week 31 — No symptoms816
week 31 — Very mild2220
week 31 — Mild1817
week 31 — Moderate1611
week 31 — Severe32
week 31 — Very severe00
week 31 — Missing34
week 32 — No symptoms615
week 32 — Very mild2520
week 32 — Mild1720
week 32 — Moderate168
week 32 — Severe33
week 32 — Very severe10
week 32 — Missing24
week 33 — No symptoms617
week 33 — Very mild2320
week 33 — Mild2214
week 33 — Moderate1413
week 33 — Severe21
week 33 — Very severe00
week 33 — Missing35
week 34 — No symptoms814
week 34 — Very mild2718
week 34 — Mild1720
week 34 — Moderate1311
week 34 — Severe22
week 34 — Very severe10
week 34 — Missing25
week 35 — No symptoms1016
week 35 — Very mild2520
week 35 — Mild1618
week 35 — Moderate1310
week 35 — Severe22
week 35 — Very severe10
week 35 — Missing34
week 36 — No symptoms715
week 36 — Very mild2622
week 36 — Mild1517
week 36 — Moderate1812
week 36 — Severe11
week 36 — Very severe10
week 36 — Missing23
week 37 — No symptoms517
week 37 — Very mild2821
week 37 — Mild1814
week 37 — Moderate1511
week 37 — Severe12
week 37 — Very severe01
week 37 — Missing34
week 38 — No symptoms717
week 38 — Very mild2524
week 38 — Mild1610
week 38 — Moderate1612
week 38 — Severe13
week 38 — Very severe00
week 38 — Missing54
week 39 — No symptoms519
week 39 — Very mild3023
week 39 — Mild1413
week 39 — Moderate169
week 39 — Severe12
week 39 — Very severe00
week 39 — Missing44
week 40 — No symptoms210
week 40 — Very mild2018
week 40 — Mild2418
week 40 — Moderate1814
week 40 — Severe23
week 40 — Very severe01
week 40 — Missing46
week 41 — No symptoms617
week 41 — Very mild2523
week 41 — Mild2016
week 41 — Moderate134
week 41 — Severe15
week 41 — Very severe00
week 41 — Missing55
week 42 — No symptoms715
week 42 — Very mild2326
week 42 — Mild1817
week 42 — Moderate154
week 42 — Severe23
week 42 — Very severe00
week 42 — Missing55
week 43 — No symptoms915
week 43 — Very mild1727
week 43 — Mild2116
week 43 — Moderate136
week 43 — Severe12
week 43 — Very severe20
week 43 — Missing74
week 44 — No symptoms616
week 44 — Very mild2423
week 44 — Mild1917
week 44 — Moderate146
week 44 — Severe23
week 44 — Very severe10
week 44 — Missing45
week 45 — No symptoms816
week 45 — Very mild2126
week 45 — Mild2214
week 45 — Moderate138
week 45 — Severe23
week 45 — Very severe00
week 45 — Missing43
week 46 — No symptoms916
week 46 — Very mild2327
week 46 — Mild1315
week 46 — Moderate177
week 46 — Severe32
week 46 — Very severe10
week 46 — Missing43
week 47 — No symptoms617
week 47 — Very mild2527
week 47 — Mild1611
week 47 — Moderate167
week 47 — Severe22
week 47 — Very severe10
week 47 — Missing46
week 48 — No symptoms1117
week 48 — Very mild2623
week 48 — Mild1413
week 48 — Moderate159
week 48 — Severe14
week 48 — Very severe20
week 48 — Missing14
week 49 — No symptoms1214
week 49 — Very mild2025
week 49 — Mild1816
week 49 — Moderate1510
week 49 — Severe20
week 49 — Very severe00
week 49 — Missing35
week 50 — No symptoms1016
week 50 — Very mild2926
week 50 — Mild1213
week 50 — Moderate158
week 50 — Severe10
week 50 — Very severe11
week 50 — Missing26
week 51 — No symptoms1215
week 51 — Very mild1825
week 51 — Mild1616
week 51 — Moderate163
week 51 — Severe22
week 51 — Very severe00
week 51 — Missing69
week 52 — No symptoms411
week 52 — Very mild2018
week 52 — Mild1419
week 52 — Moderate1612
week 52 — Severe51
week 52 — Very severe20
week 52 — Missing99
SecondaryPatient Global Impression of Change (PGIC) Category

Patient Global Impression of Change (PGIC) category by timepoint

Time frame:
from baseline to week 4
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) Category
ParticipantsBenralizumab 30 mgMepolizumab 300 mg
week 1 — Much better20
week 1 — Moderately better41
week 1 — A little better1521
week 1 — About the same4539
week 1 — A little worse25
week 1 — Moderately worse10
week 1 — Much worse00
week 1 — Missing14
week 2 — Much better72
week 2 — Moderately better76
week 2 — A little better1422
week 2 — About the same3833
week 2 — A little worse21
week 2 — Moderately worse00
week 2 — Much worse01
week 2 — Missing25
week 3 — Much better73
week 3 — Moderately better77
week 3 — A little better1527
week 3 — About the same3627
week 3 — A little worse21
week 3 — Moderately worse10
week 3 — Much worse02
week 3 — Missing23
week 4 — Much better62
week 4 — Moderately better512
week 4 — A little better1720
week 4 — About the same3531
week 4 — A little worse42
week 4 — Moderately worse01
week 4 — Much worse01
week 4 — Missing31
SecondaryWPAI-GH Endpoint, Change From Baseline by Timepoint: Absenteeism (%)

The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Subscale: Absenteeism (work time missed) (%) score, range 0-100.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
WPAI-GH Endpoint, Change From Baseline by Timepoint: Absenteeism (%)
scoreBenralizumab 30 mgMepolizumab 300 mg
week 4-1.24 ± 22.167-5.46 ± 25.387
week 80.71 ± 21.429-7.75 ± 28.680
week 126.59 ± 23.328-8.88 ± 30.513
week 1612.43 ± 28.205-7.94 ± 36.950
week 284.16 ± 17.279-3.59 ± 40.441
week 40-1.29 ± 17.181-5.02 ± 35.641
week 529.02 ± 23.971-10.99 ± 40.272
SecondaryWPAI-GH Endpoint, Change From Baseline by Timepoint up to Week 52: Subscale: Presenteeism (Impairment at Work) (%), Range 0-100.

The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Presenteeism (%) score.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
WPAI-GH Endpoint, Change From Baseline by Timepoint up to Week 52: Subscale: Presenteeism (Impairment at Work) (%), Range 0-100.
scoreBenralizumab 30 mgMepolizumab 300 mg
week 4-7.42 ± 15.2680.36 ± 16.439
week 8-2.58 ± 15.4856.43 ± 14.457
week 12-2.00 ± 12.2473.20 ± 20.355
week 162.59 ± 22.2902.31 ± 17.043
week 28-2.41 ± 19.0223.46 ± 22.793
week 40-3.91 ± 17.2520.43 ± 10.215
week 524.80 ± 34.535-6.19 ± 18.568
SecondaryWPAI-GH Endpoint, Change From Baseline by Timepoint: Work Productivity Loss (%)

The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Work productivity loss (%) score, range 0-100.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
WPAI-GH Endpoint, Change From Baseline by Timepoint: Work Productivity Loss (%)
scoreBenralizumab 30 mgMepolizumab 300 mg
week 4-7.35 ± 22.3972.14 ± 14.775
week 8-0.53 ± 23.9356.26 ± 19.154
week 121.47 ± 19.2351.24 ± 24.149
week 168.09 ± 31.0265.31 ± 23.864
week 280.05 ± 25.8446.87 ± 24.114
week 40-3.02 ± 23.3500.67 ± 14.140
week 525.82 ± 33.761-4.47 ± 27.803
SecondaryWPAI-GH Endpoint, Change From Baseline by Timepoint: Activity Impairment (%)

The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Activity impairment (%) score, range 0-100.

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Mean · score
WPAI-GH Endpoint, Change From Baseline by Timepoint: Activity Impairment (%)
scoreBenralizumab 30 mgMepolizumab 300 mg
week 4-3.97 ± 20.815-3.38 ± 19.745
week 8-3.53 ± 21.144-4.71 ± 23.466
week 12-4.56 ± 20.620-3.97 ± 20.453
week 16-3.24 ± 21.402-6.42 ± 25.268
week 28-4.41 ± 22.419-6.31 ± 27.419
week 40-7.58 ± 20.234-4.46 ± 20.235
week 52-3.28 ± 27.083-7.78 ± 25.492
SecondaryAbsolute Eosinophil Count, Change From Baseline

Absolute eosinophil count, change from baseline by timepoint up to week 52

Time frame:
from baseline to end of DB period, 52 Weeks
Reported as:
Least squares mean · cells*10^9/L
Absolute Eosinophil Count, Change From Baseline
cells*10^9/LBenralizumab 30 mgMepolizumab 300 mg
week 10.15 (0.12 to 0.18)0.39 (0.32 to 0.47)
week 40.14 (0.12 to 0.17)0.30 (0.25 to 0.36)
week 80.10 (0.08 to 0.11)0.23 (0.20 to 0.28)
week 120.11 (0.09 to 0.13)0.25 (0.20 to 0.30)
week 160.11 (0.09 to 0.13)0.24 (0.20 to 0.29)
week 200.10 (0.08 to 0.12)0.23 (0.19 to 0.28)
week 240.14 (0.12 to 0.17)0.24 (0.20 to 0.29)
week 250.14 (0.11 to 0.17)0.23 (0.19 to 0.28)
week 280.10 (0.08 to 0.12)0.24 (0.20 to 0.29)
week 320.12 (0.10 to 0.14)0.22 (0.18 to 0.27)
week 360.11 (0.09 to 0.14)0.26 (0.21 to 0.31)
week 400.09 (0.08 to 0.11)0.22 (0.18 to 0.27)
week 440.10 (0.09 to 0.13)0.24 (0.20 to 0.29)
week 480.10 (0.08 to 0.13)0.24 (0.19 to 0.29)
week 520.10 (0.08 to 0.12)0.26 (0.21 to 0.32)

Adverse events

Collected over Double-blind Treatment Period: From first dose of study drug until end of Double-blind period, up to 52 weeks. Open-label Extension Period: From the end of the Double-blind period (week 53) to the data cut-off date (10AUG2023), up to 138 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg - DB0/70 (0%)4/70 (5.7%)46/70 (65.7%)
Mepo 300 mg - DB0/70 (0%)9/70 (12.9%)56/70 (80%)
Benra 30 mg - OLE0/66 (0%)10/66 (15.2%)43/66 (65.2%)
Mepo 300 mg Switched to Benra 30 mg - OLE1/62 (1.6%)13/62 (21%)46/62 (74.2%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventBenra 30 mg - DBMepo 300 mg - DBBenra 30 mg - OLEMepo 300 mg Switched to Benra 30 mg - OLE
Eosinophilic granulomatosis with polyangiitisImmune system disorders0/700/701/662/62
Adrenal insufficiencyEndocrine disorders0/700/700/662/62
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/702/700/660/62
AppendicitisInfections and infestations0/701/700/661/62
CellulitisInfections and infestations0/700/701/661/62
Clostridium difficile infectionInfections and infestations0/700/700/661/62
Klebsiella urinary tract infectionInfections and infestations0/700/700/661/62
Pneumonia viralInfections and infestations0/700/700/661/62
Respiratory tract infectionInfections and infestations0/700/700/661/62
Upper respiratory tract infectionInfections and infestations0/700/700/661/62
Most frequent other events
Showing 10 of 25
Most frequent other events
EventBenra 30 mg - DBMepo 300 mg - DBBenra 30 mg - OLEMepo 300 mg Switched to Benra 30 mg - OLE
COVID-19Infections and infestations14/7018/7022/6627/62
SinusitisInfections and infestations5/708/7014/664/62
NasopharyngitisInfections and infestations6/7010/706/6611/62
ArthralgiaMusculoskeletal and connective tissue disorders12/708/703/661/62
HeadacheNervous system disorders12/7011/701/664/62
BronchitisInfections and infestations4/705/707/662/62
Influenza like illnessGeneral disorders4/703/707/664/62
Viral upper respiratory tract infectionInfections and infestations1/706/701/662/62
NauseaGastrointestinal disorders1/706/700/660/62
AstheniaGeneral disorders6/700/700/661/62

Baseline characteristics

All participants who were randomized and received any IP were included in the full analysis set.

Age, Continuous
Age, Continuous(years)Benralizumab 30 mgMepolizumab 300 mgTotal
Mean52.0 ± 13.9052.7 ± 14.3852.3 ± 14.10
Age, Customized
Age, Customized(participants)Benralizumab 30 mgMepolizumab 300 mgTotal
>= 18 to <= 65 years5759116
> 65 years131124
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 30 mgMepolizumab 300 mgTotal
Female453984
Male253156
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Benralizumab 30 mgMepolizumab 300 mgTotal
Hispanic or Latino404
Not Hispanic or Latino6167128
Unknown or Not Reported538
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Benralizumab 30 mgMepolizumab 300 mgTotal
White5357110
Asian9817
Other325
Not reported538
Region of Enrollment
Region of Enrollment(participants)Benralizumab 30 mgMepolizumab 300 mgTotal
North America161632
Japan448
Rest of World5050100
08

Study locations

50 sites
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Rochester, Minnesota 55905-0001, United States
  • Research Site
    Albuquerque, New Mexico 87106, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Denison, Texas 75020, United States
  • Research Site
    Seattle, Washington 98115, United States
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Hamilton, Ontario L8N 4A6, Canada
  • Research Site
    Toronto, Ontario M5G 1E2, Canada
  • Research Site
    Toronto, Ontario M5T 3A9, Canada
  • Research Site
    Dijon, 21079, France
  • Research Site
    Marseille, 13915, France
  • Research Site
    Montpellier, 34090, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Paris, 75877, France
  • Research Site
    Suresnes, 92151, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Bamberg, 96049, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Hamburg, 20251, Germany
  • Research Site
    Kirchheim, 73230, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    Ashkelon, 7830604, Israel
  • Research Site
    Beersheba, 84101, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Rehovot, 7661041, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Cuneo, 12100, Italy
  • Research Site
    Florence, 50141, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Torino, 10128, Italy
  • Research Site
    Chiba, 260-0877, Japan
  • Research Site
    Kita-gun, 761-0793, Japan
  • Research Site
    Sagamihara-shi, 228-0815, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Shinjuku-ku, 162-8666, Japan
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Leicester, LE3 9QP, United Kingdom
  • Research Site
    London, SE19RT, United Kingdom
  • Research Site
    Portsmouth, PO6 3LY, United Kingdom
09

References and documents

Publications

  • Nair PK, Hellmich B, Bourdin A, Jayne DRW, Roufosse F, Khalidi N, Borjesson Sjo L, Fan Y, McCrae C, Necander S, Rodriguez-Suarez E, Shavit A, Walton C, Merkel PA, Wechsler ME. The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol. 2026 Mar;78(3):695-704. doi: 10.1002/art.43398. Epub 2025 Nov 30. PubMed 40977418 ↗
  • Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Borjesson Sjo L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. PubMed 38393328 ↗
  • Serling-Boyd N, Wallace ZS. Management of primary vasculitides with biologic and novel small molecule medications. Curr Opin Rheumatol. 2021 Jan;33(1):8-14. doi: 10.1097/BOR.0000000000000756. PubMed 33164993 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Aug 2023, 45 months.

Results were first posted in Jan 2025, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2019
First posted
Nov 8, 2019
StartActual
Oct 29, 2019
Primary completionActual
Aug 10, 2023
CompletionEst.
Nov 30, 2026
Results first posted
Jan 14, 2025
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40977418 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40977418 ↗
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04157348
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 8, 2019
Start date
Oct 29, 2019
Primary completion
Aug 10, 2023
Completion
Nov 30, 2026 (estimated)
Results posted
Jan 14, 2025
Last update
Nov 9, 2026

Study contacts

Michael Wechsler, MD
principal investigator · National Jewish Health, 1400 Jackson St Denver, CO 80206

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion